Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Desflurane,Brain Natriuretic Peptide and Cardiac Surgery

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
L'enllaç es desa al porta-retalls
EstatCompletat
Patrocinadors
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Col·laboradors
Trakya University Faculty of Medicine Hospital

Paraules clau

Resum

During coronary artery bypass grafting (CABG) operations with cardiopulmonary bypass (CPB), the use of desflurane continuously or intermittently may have effects on serum brain natriuretic peptide (BNP) levels. The aim is to investigate the association between desflurane, serum BNP values, and clinical outcomes during CABG operations. In a prospective, randomized, double-blinded study, desflurane inhalational anesthesia was administered either continuously or intermittently (Group 1; n=60 versus Group 2; n=62). The preoperative and postoperative BNP levels at 24, 48 and 72 hours after surgery were collected. Outcomes were recorded.

Descripció

Background: During coronary artery bypass grafting (CABG) operations with cardiopulmonary bypass (CPB), the use of desflurane continuously or intermittently may have effects on serum brain natriuretic peptide (BNP) levels.

Aim of the study: The aim is to investigate the association between desflurane, serum BNP values, and clinical outcomes during CABG operations.

Material and methods: In a prospective, randomized, double-blinded study, desflurane inhalational anesthesia was administered either continuously or intermittently (Group 1; n=60 versus Group 2; n=62). The preoperative and postoperative BNP levels at 24, 48 and 72 hours after surgery were collected. Outcomes were recorded. Randomization into two groups was performed using sealed envelopes. The sequentially numbered assignments of participants were concealed in these envelopes during the study. The patients enrolled in the study receive an allocation to a group after anesthesia induction by health care personnel after the opening of the envelope. The observers were blinded to the anesthetic protocol. Caregivers were not blinded, but they did not participate in data collection or data interpretation. Therefore, the study protocol is considered double-blinded, masked to observers. Inclusion criteria include; 18 to 75 years of age, body mass index of 25 to 31, ejection fraction≥50%. Exclusion criteria include; repeat cardiac surgery, emergent surgery, preoperative coagulation disorder, preoperative congestive heart failure, ejection fraction <49%, preoperative renal dysfunction (serum creatinine>1.3 mg/dL), dialysis, preoperative hepatic dysfunction (serum aspartate/alanine amino transferase>40 U/L), preoperative electrolyte imbalance, history of pancreatitis or current corticosteroid treatment.The primary endpoint was to determine preoperative and postoperative BNP values 24, 48 and 72 hours after surgery. The secondary endpoint was the relation between BNP values and clinical outcomes such as; 1-Aortic cross-clamp time, 2-Cardiopulmonary bypass time, 3-The use of inotropic support, 4-Intra-aortic balloon pump, 5-Duration of mechanical ventilation (>48 hours), 6-Development of pneumonia, 7-Perioperative myocardial infarction, 8-Cerebrovascular event (stroke or transient ischemic attack), seizure, 9-Atrial fibrillation and other rhythm disturbances, 10-Need for renal replacement therapy (RRT), 11-Reoperation secondary to bleeding, 12-Intensive care unit stay (>3 days), 13-Hospital stay and, 14-Thirty-day mortality.

Statistical analysis. The sample size was calculated according to the comparison of serum BNP values in a previous study and a sample size of 58 patients per group would be required with 80% power and the conventional 2-sided type 1 error of 5%. A multiple logistic regression analysis was performed to assess the predictive factors for weaning failure from mechanical ventilation, and the significance level was set at a p-value of less than 0.10 in the univariate model. To determine the best cut-off for preoperative BNP value to predict the development of prolonged mechanical ventilation, we calculated the area under the receiver operating characteristic curve.

Dates

Darrera verificació: 12/31/2019
Primer enviat: 01/12/2020
Inscripció estimada enviada: 01/19/2020
Publicat per primera vegada: 01/22/2020
Última actualització enviada: 01/19/2020
Publicació de l'última actualització: 01/22/2020
Data d'inici de l'estudi real: 08/31/2013
Data estimada de finalització primària: 08/30/2014
Data estimada de finalització de l’estudi: 09/29/2014

Condició o malaltia

Brain Natriuretic Peptide
Coronary Artery Bypass Graft Surgery
Cardiac Surgery
Cardiopulmonary Bypass
Desflurane
Outcome

Intervenció / tractament

Drug: Desflurane Inhalational agent

Fase

-

Grups de braços

BraçIntervenció / tractament
Active Comparator: Desflurane Continuous
In Group 1 of 60 patients, desflurane inhalational agent was administered continuously during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg. For maintenance, in Group 1 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% during the whole surgical procedure and intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 1 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
Active Comparator: Desflurane Intermittent
In Group 2 of 60 patients, desflurane inhalational agent was administered intermittently during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg/kg. For maintenance, in Group 2 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% before and after the cardiopulmonary bypass procedure as intermittently with the addition of intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 2 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.

Criteris d'elegibilitat

Edats elegibles per estudiar 18 Years Per a 18 Years
Sexes elegibles per estudiarAll
Accepta voluntaris saludables
Criteris

Inclusion Criteria:

- Eighteen to seventy-five years of age,

- Body mass index values between twenty-five and thirty-one,

- Ejection fraction greater than or equal to 50%.

Exclusion Criteria:

- Repeat cardiac surgery,

- Emergent surgery,

- Preoperative coagulation disorder,

- Preoperative congestive heart failure,

- Ejection fraction less than 49%,

- Preoperative renal dysfunction (serum creatinine value of greater than 1.3 mg/dL),

- Dialysis,

- Preoperative hepatic dysfunction (serum aspartate/alanine amino transferase values of greater than 40 U/L),

- Preoperative electrolyte imbalance,

- History of pancreatitis,

- Current corticosteroid treatment.

Resultat

Mesures de resultats primaris

1. Serum BNP values before the cardiac surgery [One day before cardiac surgery.]

Serum BNP values were collected from a blood sample of each patient one day before cardiac surgery

2. Serum BNP values after the cardiac surgery at 24 hours [After operation at 24 hours after cardiac surgery.]

Serum BNP values were collected from a blood sample of each patient after cardiac surgery

3. Serum BNP values after the cardiac surgery at 48 hours [After operation at 48 hours after cardiac surgery.]

Serum BNP values were collected from a blood sample of each patient after cardiac surgery

4. Serum BNP values after the cardiac surgery at 72 hours [After operation at 72 hours after cardiac surgery.]

Serum BNP values were collected from a blood sample of each patient after cardiac surgery

5. Serum BNP values before and after the cardiac surgery [After collection of the data and during statistical analysis]

The collected serum BNP values were compared with each other by repeated measure analysis

Mesures de resultats secundaris

1. Outcome aortic cross-clamp time [During operative time period of cardiac surgery]

A relation between serum BNP values and aortic cross-clamp time

2. Outcome cardiopulmonary bypass time [During operative time period of cardiac surgery]

A relation between serum BNP values and cardiopulmonary bypass time

3. Outcome use of inotropic support [During operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and use of inotropic support

4. Outcome use of Intra-aortic balloon pump [During operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and use of Intra-aortic balloon pump

5. Outcome duration of mechanical ventilation (>48 hours) [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and duration of mechanical ventilation (>48 hours)

6. Outcome development of pneumonia [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and development of pneumonia

7. Outcome parameters [During operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and perioperative myocardial infarction

8. Outcome cerebrovascular event or seizure [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and cerebrovascular event (stroke or transient ischemic attack) or seizure

9. Outcome atrial rhythm disturbances [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and atrial fibrillation and other atrial rhythm disturbances

10. Outcome ventricular rhythm disturbances [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and ventricular rhythm disturbances

11. Outcome renal replacement therapy [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and need for renal replacement therapy (RRT)

12. Outcome reoperation [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and reoperation secondary to bleeding

13. Outcome intensive care unit stay [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and intensive care unit stay (>3 days)

14. Outcome hospital stay [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and intensive care unit stay (>3 days)

15. Outcome thirty-day mortality [After operative time period of cardiac surgery and during intensive care unit stay]

A relation between serum BNP values and thirty-day mortality

Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge